L-4FPG | CAS# 19883-57-9 | ASCT1/2 Inhibitor

MedKoo Cat#: 564895 | Name: L-4FPG

Description:

WARNING: This product is for research use only, not for human or veterinary use.

L-4FPG is an inhibitor of the neutral amino acid transporters ASCT1 and ASCT2. L-4FPG shows good brain penetration and potently reduces amphetamine-induced hyperlocomotion.

Chemical Structure

L-4FPG

CAS#19883-57-9

Theoretical Analysis

MedKoo Cat#: 564895

Name: L-4FPG

CAS#: 19883-57-9

Chemical Formula: C8H8FNO2

Exact Mass: 169.0539

Molecular Weight: 169.16

Elemental Analysis: C, 56.80; H, 4.77; F, 11.23; N, 8.28; O, 18.92

Price and Availability

Size	Price	Availability
1g	USD 150.00	Ready to ship
2g	USD 225.00	Ready to ship
5g	USD 350.00	2 Weeks
25g	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

L4FPG; L 4FPG; L-4FPG

IUPAC/Chemical Name

2-(4-Fluorophenyl)-L-glycine

InChi Key

JKFYKCYQEWQPTM-ZETCQYMHSA-N

InChi Code

InChI=1S/C8H8FNO2/c9-6-3-1-5(2-4-6)7(10)8(11)12/h1-4,7H,10H2,(H,11,12)/t7-/m0/s1

SMILES Code

N[C@@H](C1=CC=C(F)C=C1)C(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#C9B11B19

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

L-4FPG is an inhibitor of the neutral amino acid transporters ASCT1 and ASCT2.

In vitro activity:

TBD

In vivo activity:

L-4FPG was tested for its effects on amphetamine-induced hyperlocomotion in a mouse model of schizophrenia. For L-4FPG (Fig. 3), a dose-dependent reduction was observed (overall treatment effect was significant by one-way ANOVA, F(4,34) = 3.07; P = 0.03) with a lowest effective dose for L-4FPG of 0.3 mg/kg (post hoc Dunnett’s test, P = 0.023); at 3 mg/kg the effect was not significant, indicating that a U-shaped dose-response relationship exists. Reference: J Pharmacol Exp Ther. 2018 Nov;367(2):292-301. https://jpet.aspetjournals.org/content/367/2/292.long

Preparing Stock Solutions

The following data is based on the product molecular weight 169.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Li YX, Yang JY, Alcantara M, Abelian G, Kulkarni A, Staubli U, Foster AC. Inhibitors of the Neutral Amino Acid Transporters ASCT1 and ASCT2 Are Effective in In Vivo Models of Schizophrenia and Visual Dysfunction. J Pharmacol Exp Ther. 2018 Nov;367(2):292-301. doi: 10.1124/jpet.118.251116. Epub 2018 Aug 31. PMID: 30171039.

In vitro protocol:

TBD

In vivo protocol:

1: Li YX, Yang JY, Alcantara M, Abelian G, Kulkarni A, Staubli U, Foster AC. Inhibitors of the Neutral Amino Acid Transporters ASCT1 and ASCT2 Are Effective in In Vivo Models of Schizophrenia and Visual Dysfunction. J Pharmacol Exp Ther. 2018 Nov;367(2):292-301. doi: 10.1124/jpet.118.251116. Epub 2018 Aug 31. PubMed PMID: 30171039.